Peer-reviewed veterinary case report
Probiotics effects on colon polyamines in dogs with IBD and polyps
By Rossi, G et al.·Published in Beneficial microbes·2018·1 School of Biosciences and Veterinary Medicine, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of probiotic bacteria on mucosal polyamines levels in dogs with IBD and colonic polyps: a preliminary study.
- Species:
- dog
Plain-English summary
A group of dogs with inflammatory bowel disease (IBD) and colonic polyps were given a special probiotic supplement for 60 days to see if it would help their symptoms. Owners noticed improvements in their dogs' overall health, with significant reductions in clinical signs of IBD and better histology scores, indicating less inflammation. In dogs with polyps, the treatment also led to lower levels of certain harmful substances and increased signs of cell death in the polyps, suggesting the probiotics might help reduce growth and inflammation. Overall, the probiotic treatment showed promise in improving gut health in these dogs.
People also search for: dog inflammatory bowel disease treatment · probiotics for dogs with colonic polyps · dog gut health supplements
Abstract
Spermine (SPM) and its precursor putrescine (PUT), regulated by ornithine decarboxylase (ODC) and diamino-oxidase (DAO), are polyamines required for cell growth and proliferation. Only a few studies have investigated the anti-inflammatory and tumour inhibitory properties of probiotics on mucosal polyamine levels. We investigated the effects of a high concentration multistrain probiotic for human use on colonic polyamine biosynthesis in dogs. Histological sections (inflammatory bowel disease, n=10; polyposis, n=5) were assessed after receiving 112 to 225×10lyophilised bacteria daily for 60 days at baseline (T0) and 30 days after treatment end (T90). Histology scores, expression of PUT, SPM, ODC and DAO, and a clinical activity index (CIBDAI) were compared at T0 and T90. In polyps, cellular proliferation (Ki-67 expression), and apoptosis (caspase-3 protein expression) were also evaluated. After treatment, in inflammatory bowel disease significant decreases were observed for CIBDAI (P=0.006) and histology scores (P<0.001); PUT, SPM and ODC expression increased (P<0.01). In polyps, a significant decrease in polyamine levels, ODC activity, and Ki-67, and a significant increase in caspase-3 positivity and DAO expression (P=0.005) was noted. Our results suggest potential anti-proliferative and anti-inflammatory effects of the probiotic mixture in polyps and inflammation, associated with reduced mucosal infiltration and up-regulation of PUT, SPM, and ODC levels.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29022381/